D
Donald P. Francis
Researcher at Centers for Disease Control and Prevention
Publications - 100
Citations - 11581
Donald P. Francis is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Vaccination & Hepatitis. The author has an hindex of 48, co-authored 100 publications receiving 11164 citations. Previous affiliations of Donald P. Francis include City University of New York & University of Medicine and Dentistry of New Jersey.
Papers
More filters
Journal ArticleDOI
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Supachai Rerks-Ngarm,Punnee Pitisuttithum,Sorachai Nitayaphan,Jaranit Kaewkungwal,Joseph Chiu,Robert Paris,Nakorn Premsri,Chawetsan Namwat,Mark de Souza,Elizabeth Adams,Michael Benenson,Sanjay Gurunathan,Jim Tartaglia,John G. McNeil,Donald P. Francis,Donald Stablein,Deborah L. Birx,Supamit Chunsuttiwat,Chirasak Khamboonruang,Prasert Thongcharoen,Merlin L. Robb,Nelson L. Michael,Prayura Kunasol,Jerome H. Kim +23 more
TL;DR: This ALVAC-HIV and AIDSVAX B/E vaccine regimen may reduce the risk of HIV infection in a community-based population with largely heterosexual risk and offer insight for future research.
Journal ArticleDOI
Acute Hepatitis B Virus Infection: Relation of Age to the Clinical Expression of Disease and Subsequent Development of the Carrier State
Brian J. McMahon,Wallace L.M. Alward,David B. Hall,William L. Heyward,Thomas R. Bender,Donald P. Francis,James E. Maynard +6 more
TL;DR: Yupik Eskimos of southwestern Alaska have the highest known prevalence of hepatitis B virus infection of any general population in the United States and the risk of becoming a carrier was inversely related to the age of the patient at the time of infection.
Journal ArticleDOI
Long-Term Immunogenicity and Efficacy of Hepatitis B Vaccine in Homosexual Men
Stephen C. Hadler,Donald P. Francis,James E. Maynard,Sumner E. Thompson,Franklyn N. Judson,Dean F. Echenberg,David G. Ostrow,Paul M. O'Malley,Kent A. Penley,Norman L. Altman,Erwin H. Braff,Gregory F. Shipman,Patrick J. Coleman,Eric J. Mandel +13 more
TL;DR: Both antibody loss and the risk of severe disease should be considered when booster-dose strategies for the hepatitis B vaccine are being designed.
Journal ArticleDOI
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination
Nicole L. Yates,Nicole L. Yates,Hua-Xin Liao,Hua-Xin Liao,Youyi Fong,Allan C. deCamp,Nathan Vandergrift,Nathan Vandergrift,William T. Williams,William T. Williams,S. Munir Alam,S. Munir Alam,Guido Ferrari,Guido Ferrari,Zhi Yong Yang,Kelly E. Seaton,Kelly E. Seaton,Phillip W. Berman,Michael D. Alpert,David T. Evans,Robert J. O'Connell,Donald P. Francis,Faruk Sinangil,Carter Lee,Sorachai Nitayaphan,Supachai Rerks-Ngarm,Jaranit Kaewkungwal,Punnee Pitisuttithum,James Tartaglia,Abraham Pinter,Susan Zolla-Pazner,Peter B. Gilbert,Gary J. Nabel,Nelson L. Michael,Jerome H. Kim,David C. Montefiori,David C. Montefiori,Barton F. Haynes,Barton F. Haynes,Georgia D. Tomaras +39 more
TL;DR: HIV-1–specific IgG3 responses were not long-lived, which was consistent with the waning efficacy of the RV144 vaccine, and should be evaluated in future HIV-1 vaccine efficacy trials to further refine immune correlates of protection.
Journal ArticleDOI
The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men.
Donald P. Francis,Stephen C. Hadler,Sumner E. Thompson,James E. Maynard,David G. Ostrow,Norman L. Altman,Erwin H. Braff,Paul M. O'Malley,Donald Hawkins,Franklyn N. Judson,Kent A. Penley,Thom Nylund,Graham Christie,Frank Meyers,Joseph N. Moore,Ann Gardner,Irene L. Doto,Joe H. Miller,Gladys H. Reynolds,Bert L. Murphy,Charles A. Schable,Brian T. Clark,James Curran,Allan G. Redeker +23 more
TL;DR: This vaccine appears to be safe, immunogenic, and efficacious in preventing infection with hepatitis B virus.